Stenocare (Denmark) Top Management
STENO Stock | DKK 0.67 0.01 1.52% |
Stenocare employs about 4 people. The company is managed by 4 executives with a total tenure of roughly 10 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Evaluation of Stenocare's management performance can provide insight into the firm performance.
Thomas Schnegelsberg Insider CoFounder CEO |
Soren Kjaer Insider COO CoFounder |
Stenocare |
Stenocare Management Team Effectiveness
The company has return on total asset (ROA) of (0.2782) % which means that it has lost $0.2782 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4924) %, meaning that it generated substantial loss on money invested by shareholders. Stenocare's management efficiency ratios could be used to measure how well Stenocare manages its routine affairs as well as how well it operates its assets and liabilities.Stenocare Workforce Comparison
Stenocare AS is currently regarded as top stock in number of employees category among its peers. The total workforce of Drug Manufacturers—Specialty & Generic industry is at this time estimated at about 29,884. Stenocare adds roughly 4.0 in number of employees claiming only tiny portion of equities under Drug Manufacturers—Specialty & Generic industry.
Stenocare AS Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Stenocare AS Price Series Summation is a cross summation of Stenocare price series and its benchmark/peer.
Stenocare Notable Stakeholders
A Stenocare stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Stenocare often face trade-offs trying to please all of them. Stenocare's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Stenocare's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Thomas Schnegelsberg | CoFounder CEO | Profile | |
Soren Kjaer | COO CoFounder | Profile | |
Peter Johansen | Chief Officer | Profile | |
Rolf Petersen | CoFounder Officer | Profile |
About Stenocare Management Performance
The success or failure of an entity such as Stenocare AS often depends on how effective the management is. Stenocare management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Stenocare management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Stenocare management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Stenocare AS cultivates, produces, imports, sells, and distributes prescription-based medical cannabis products in the Danish and European markets. The company was founded in 2017 and is headquartered in Allerd, Denmark. STENOCARE is traded on Copenhagen Stock Exchange in Denmark.
Please note, the presentation of Stenocare's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Stenocare's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Stenocare's management manipulating its earnings.
Stenocare Workforce Analysis
Traditionally, organizations such as Stenocare use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Stenocare within its industry.Stenocare Manpower Efficiency
Return on Stenocare Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 3.2M | |
Net Loss Per Executive | 3.2M |
Complementary Tools for Stenocare Stock analysis
When running Stenocare's price analysis, check to measure Stenocare's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Stenocare is operating at the current time. Most of Stenocare's value examination focuses on studying past and present price action to predict the probability of Stenocare's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Stenocare's price. Additionally, you may evaluate how the addition of Stenocare to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data |